[{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diabetologia Publishes Results Highlighting Efficacy of the Diabetes Vaccine Diamyd\u00ae in Genetically Defined Subgroups of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical's Analysis of Prevention Trials and Intralymphatic Pilot Trial with the Diabetes Vaccine Diamyd\u00ae Support a Positive Trend in Genetically Defined Subgroups of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase IIb Topline Results Demonstrate a Significant Treatment Effect of Diamyd\u00ae in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Pauses Start of DIAGNODE-3 In the US Pending Clarification on Study Drug","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Updated Results From Clinical Trial With Diamyd\u00ae Presented Today At Diabetes Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Partial Clinical Hold on Diamyd\u00ae Phase III Trial Lifted by the FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Diamyd Medical Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Announces New Phase 3 Data Reinforcing Long-Term Safety and Efficacy of Octreotide SC Depot (CAM2029) in Patients with Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Camurus"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Registrational Phase III Trial in Type 1 Diabetes with Diamyd\u00ae Expands to the US","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Diamyd Medical AB"},{"orgOrder":0,"company":"Sigrid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sigrid Therapeutics Announces First Patient Treated with SiPore21\u00ae Medical Device for Sustained Diabetes and Obesity Control","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Sigrid Therapeutics"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"DiaUnion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diamyd Medical Partners with DiaUnion to Recruit Participants for Type 1 Diabetes Prevention Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Diamyd Medical AB"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The partnership aims to identify participants for the DiaPrecise trial, an open-label trial evaluating the safety, feasibility and immune response of intralymphatic injections of Diamyd (recombinant human glutamic acid decarboxylase) in children at risk of type 1 diabetes.
Lead Product(s):
Recombinant Human Glutamic Acid Decarboxylase
SiPore15 is a taste-and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide, which is investigated for the treatment of Type2 Diabetes Mellitus and Overweight.
Lead Product(s):
Synthetic Amorphous Silicon Dioxide
Diamyd® is an antigen-specific immunotherapy for the treatment of autoimmune diabetes. Diamyd® is based on the protein GAD65, an endogenous antigen involved in the pathology of autoimmune diabetes.
Lead Product(s):
Recombinant Human Glutamic Acid Decarboxylase
CAM2029 is a ready-to-use octreotide for subcutaneous administration under development for treatment of acromegaly as well as gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD).
The collaboration aims to support Diamyd Medical's ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd (recombinant human glutamic acid decarboxylase), an antigen-specific immunotherapy for the preservation of endogenous insulin production.
Lead Product(s):
Recombinant Human Glutamic Acid Decarboxylase
Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in Company's European Phase IIb trial.
The diabetes vaccine Diamyd® (GAD-alum) is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA.
The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The Phase III trial DIAGNODE-3, with a planned start date later during 2021 and primary completion end of 2025.
In line with previous large-scale analysis of trials involving subcutaneous administration of Diamyd®, the reults, encompassing a total of 109 patients, showed a statistically significant effect in the predefined HLA (Human Leukocyte Antigen) subgroup of trial participants.
The analysis while not reaching statistical significance, supports a positive effect of subcutaneous injections of Diamyd® on delaying the progression to type 1 diabetes in HLA-type DR3-DQ2 group while no benefit vs placebo is seen in individuals negative for HLA-type DR3-DQ2.